title: The prognostic implications of macrophages expressing proliferating cell nuclear antigen in breast cancer depend on immune context.
abstract: Tumor associated macrophages (TAMs) are recruited from the circulation to the tumor site, and can undergo a spectrum of phenotypic changes, with two contrasting activation states described in the literature: the M1 and M2 phenotypes. We previously identified a population of TAMs that express proliferating cell nuclear antigen (PCNA) and are associated with high grade, hormone receptor negative breast cancers and poor outcomes. In the present exploratory study we again found that high PCNA(+) TAM counts in pre-treatment tumor biopsies (102 invasive breast cancer cases from the I-SPY 1 Trial, a prospective neoadjuvant trial with serial core biopsies and gene array data) were associated with high grade, hormone receptor negativity, and decreased recurrence free survival. We explored the association of these PCNA(+) TAMs with the expression of M1 and M2 related genes and, contrary to expectation, observed that high PCNA(+) TAM levels were associated with more M1- than M2-related genes. An immune gene signature, derived from cytotoxic T cell and MHC Class II genes (Tc/ClassII), was developed and we found that high PCNA(+) TAM counts, in the context of a low Tc/ClassII signature score, were associated with significantly worse recurrence free survival in all cases and in hormone receptor negative only cases. We observed similar results using a gene signature-proxy for PCNA(+) TAMs in a larger independent set of 425 neoadjuvant-treated breast cancer cases. The results of this exploratory study indicate that high numbers of PCNA(+) TAMs, in the absence of an anti-tumor immune microenvironment (as indicated by a low Tc/ClassII signature score), are associated with poor outcomes in breast cancer patients treated with neoadjuvant chemotherapy. This, along with the observation that PCNA(+) TAMs were associated predominantly with M1-related genes, may provide new insights into the role of the immune microenvironment in breast cancer.
authors.affiliation: Department of Surgery, University of California, San Francisco, San Francisco, California, United States of America.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Campbell
authors.forename: Denise
authors.initials: D
authors.lastname: Wolf
authors.forename: Rita A
authors.initials: RA
authors.lastname: Mukhtar
authors.forename: Vickram
authors.initials: V
authors.lastname: Tandon
authors.forename: Christina
authors.initials: C
authors.lastname: Yau
authors.forename: Alfred
authors.initials: A
authors.lastname: Au
authors.forename: Frederick
authors.initials: F
authors.lastname: Baehner
authors.forename: Laura
authors.initials: L
authors.lastname: van't Veer
authors.forename: Donald
authors.initials: D
authors.lastname: Berry
authors.forename: Laura J
authors.initials: LJ
authors.lastname: Esserman
mesh_terms: D014408:Biomarkers, Tumor / Q000378:metabolism*; D001943:Breast Neoplasms / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008264:Macrophages / Q000378:metabolism*; D011379:Prognosis; D018809:Proliferating Cell Nuclear Antigen / Q000378:metabolism*
chemical_list: D014408:Biomarkers, Tumor; D018809:Proliferating Cell Nuclear Antigen